Glioblastoma multiform (GBM) is the most aggressive form of primary brain cancers, with dramatic poor outcomes after diagnosis and first-line treatment. The high rate of recurrences of this tumor is related to the persistence of cancer stem cells even after surgery, radiotherapy and adjuvant chemotherapy. These cancer stem cells, specifically called GBM stem cells (GSC), have been found in the vicinity of the primary tumor, and the subventricular zone parenchyma. Among other characteristics, these GSC overexpress a specific chemokine receptor named CXCR4 and the B7-H3 immune checkpoint as well. Whereas the specific pathways involved by B7-H3 activation are not completely unraveled today, we know that CXCR4 stimulation by its endogenous ligand CXCL12 results in a variety of cellular response like tissue invasion, radioresistance, angiogenesis, cell proliferation and survival. Thus, CXCR4 and B7-H3 are potential therapeutic targets that could contribute to a better treatment of patient suffering from GBM. Recent innovations in nuclear medicine and radiopharmacy allow the delivery of ionizing radiation directly on the cancer cells thanks to the specific binding of cancer seeking career molecules. This extremely promising technic, called targeted radionuclide therapy (TRNT) requires a multidisciplinary approach at the crossroad of biology, nuclear sciences and medicine. Our project focuses on the development of advanced TRNT towards CXCR4 and B7-H3 targets with high translational potential for medical application in the field of neuro-oncology.